Quoin Pharmaceuticals, Ltd. (QNRX)Healthcare | Biotechnology | Ashburn, United States | NasdaqCM
6.46 USD
-0.12
(-1.824%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.58 +0.12 (1.858%) ⇧ (April 17, 2026, 7:46 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:09 a.m. EDT
QNRX exhibits high short-term volatility due to recent $104.5M funding, but the forecasting model predicts an adjusted -11.6% price drop over the next 45 days, signaling a sell signal for technicians despite the 'strong buy' analyst consensus. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.266130 |
| MSTL | 0.266459 |
| AutoETS | 0.266905 |
| AutoARIMA | 0.476776 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 2.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.107 |
| Excess Kurtosis | -0.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.712 |
| Market Cap | 11,651,430 |
| Forward P/E | -2.05 |
| Beta | 1.82 |
| Website | https://quoinpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.13932979 |
| Address1 | 42,127 Pleasant Forest Court |
| All Time High | 1,417,500.0 |
| All Time Low | 5.01 |
| Ask | 6.5 |
| Ask Size | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 28,630 |
| Average Daily Volume3 Month | 99,396 |
| Average Volume | 99,396 |
| Average Volume10Days | 28,630 |
| Beta | 1.821 |
| Bid | 5.6 |
| Bid Size | 1 |
| Book Value | 8.756 |
| City | Ashburn |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.46 |
| Current Ratio | 3.607 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.525 |
| Day Low | 6.3401 |
| Debt To Equity | 17.712 |
| Display Name | Quoin Pharmaceuticals |
| Dividend Date | 1,571,788,800 |
| Earnings Call Timestamp End | 1,710,419,400 |
| Earnings Call Timestamp Start | 1,710,419,400 |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,483,400 |
| Ebitda | -16,190,716 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -24.173 |
| Enterprise Value | 391,378,528 |
| Eps Current Year | -5.55 |
| Eps Forward | -3.15 |
| Eps Trailing Twelve Months | -14.8 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.7111 |
| Fifty Day Average Change | -1.2511001 |
| Fifty Day Average Change Percent | -0.16224664 |
| Fifty Two Week Change Percent | 13.93298 |
| Fifty Two Week High | 41.8 |
| Fifty Two Week High Change | -35.34 |
| Fifty Two Week High Change Percent | -0.8454546 |
| Fifty Two Week Low | 5.27 |
| Fifty Two Week Low Change | 1.19 |
| Fifty Two Week Low Change Percent | 0.22580646 |
| Fifty Two Week Range | 5.27 - 41.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,058,200,000 |
| Float Shares | 50,449,161 |
| Forward Eps | -3.15 |
| Forward P E | -2.0507936 |
| Free Cashflow | -7,961,312 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02933 |
| Held Percent Institutions | 0.49269 |
| Implied Shares Outstanding | 1,803,627 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,156,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. |
| Long Name | Quoin Pharmaceuticals, Ltd. |
| Market | us_market |
| Market Cap | 11,651,430 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_593010770 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -15,804,655 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,552,228 |
| Number Of Analyst Opinions | 3 |
| Open | 6.525 |
| Operating Cashflow | -13,540,994 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 703 980 4182 |
| Post Market Change | 0.119999886 |
| Post Market Change Percent | 1.8575834 |
| Post Market Price | 6.58 |
| Post Market Time | 1,776,469,580 |
| Previous Close | 6.58 |
| Price Eps Current Year | -1.1639639 |
| Price Hint | 2 |
| Price To Book | 0.73777986 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.379 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.12 |
| Regular Market Change Percent | -1.82371 |
| Regular Market Day High | 6.525 |
| Regular Market Day Low | 6.3401 |
| Regular Market Day Range | 6.3401 - 6.525 |
| Regular Market Open | 6.525 |
| Regular Market Previous Close | 6.58 |
| Regular Market Price | 6.46 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 20,151 |
| Return On Assets | -0.56408 |
| Return On Equity | -1.4159 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,803,627 |
| Shares Percent Shares Out | 0.0523 |
| Shares Short | 94,409 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 14,672 |
| Short Name | Quoin Pharmaceuticals, Ltd. |
| Short Percent Of Float | 0.052600004 |
| Short Ratio | 0.43 |
| Source Interval | 15 |
| State | VA |
| Symbol | QNRX |
| Target High Price | 40.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 29.66667 |
| Target Median Price | 35.0 |
| Total Cash | 18,745,260 |
| Total Cash Per Share | 0.297 |
| Total Debt | 2,323,733 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -14.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.93803 |
| Two Hundred Day Average Change | -3.4780302 |
| Two Hundred Day Average Change Percent | -0.3499718 |
| Type Disp | Equity |
| Volume | 20,151 |
| Website | https://quoinpharma.com |
| Zip | 20,148-7349 |